E
Sell
3/28/2025Downgrade
CG Oncology, Inc. (CGON) was downgraded to E+ from D- on 3/28/2025 due to a decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.3039 to -$0.4605, EBIT declined 34.47% from -$28.3M to -$38.05M, and operating cash flow declined 29.79% from -$15.92M to -$20.66M.
D
Sell
3/21/2025Upgraded
CG Oncology, Inc. (CGON) was upgraded to D- from E+ on 3/21/2025 due to an increase in the volatility index.
E
Sell
3/5/2025Downgrade
CG Oncology, Inc. (CGON) was downgraded to E+ from D- on 3/5/2025 due to a decline in the total return index and volatility index.
D
Sell
2/14/2025Upgraded
CG Oncology, Inc. (CGON) was upgraded to D- from E+ on 2/14/2025 due to an increase in the valuation index.
E
Sell
1/28/2025Downgrade
CG Oncology, Inc. (CGON) was downgraded to E+ from D- on 1/28/2025 due to a decline in the total return index, valuation index and volatility index.
D
Sell
12/27/2024Upgraded
CG Oncology, Inc. (CGON) was upgraded to D- from E+ on 12/27/2024 due to an increase in the valuation index.
E
Sell
12/12/2024Downgrade
CG Oncology, Inc. (CGON) was downgraded to E+ from D- on 12/12/2024 due to a decline in the volatility index and total return index.
D
Sell
11/14/2024Downgrade
CG Oncology, Inc. (CGON) was downgraded to D- from D on 11/14/2024 due to a substantial decline in the efficiency index, growth index and total return index. Total revenue declined 61.26% from $111 to $43, EBIT declined 9.45% from -$25.85M to -$28.3M, and net income declined 7.95% from -$18.9M to -$20.41M.
D
Sell
5/14/2024None
CG Oncology, Inc. (CGON) was downgraded to D from U on 05/14/2024.
